Panacea Medical Technologies

Accuray CyberKnife® Robotic Radiotherapy Platform Could Significantly Improve Survival in Early-Stage Breast Cancer Patients

Retrieved on: 
Monday, October 25, 2021

SUNNYVALE, Calif., Oct. 25, 2021 /PRNewswire/ --Accuray Incorporated(NASDAQ: ARAY) announced today that a study published in Frontiers in Oncology found early-stage breast cancer patients could experience significant improvements in survival if treated with accelerated partial breast irradiation (APBI) delivered using the Accuray CyberKnife robotic radiotherapy platform.

Key Points: 
  • SUNNYVALE, Calif., Oct. 25, 2021 /PRNewswire/ --Accuray Incorporated(NASDAQ: ARAY) announced today that a study published in Frontiers in Oncology found early-stage breast cancer patients could experience significant improvements in survival if treated with accelerated partial breast irradiation (APBI) delivered using the Accuray CyberKnife robotic radiotherapy platform.
  • The addition of radiotherapy can extend survival that may be offset by the development of a secondary cancer like lung tumors many years following treatment.
  • This study reinforces the unparalleled accuracy of a 4-like robotic CyberKnife platform and shows its tremendous potential as a treatment for early-stage breast cancer," said Suzanne Winter, president at Accuray.
  • Breast cancer stage distribution and number of new cases were obtained from the North American Association of Central Cancer Registries (NAACCR).